Search Results - "Strutton, David R."

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States by Rubin, Jaime L, McGarry, Lisa J, Strutton, David R, Klugman, Keith P, Pelton, Stephen I, Gilmore, Kristen E, Weinstein, Milton C

“…Abstract The 7-valent pneumococcal conjugate vaccine (PCV7) has dramatically decreased pneumococcal disease incidence, and the 13-valent vaccine (PCV13)…”
Get full text

Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden by Klok, Rogier M., PhD, Lindkvist, Rose-Marie, MSc, Ekelund, Mats, PhD, Farkouh, Raymond A., PhD, Strutton, David R., PhD

“…Abstract Background The introduction of a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV7) had profound public health effects across the…”
Get full text

Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States by McGarry, Lisa J, Gilmore, Kristen E, Rubin, Jaime L, Klugman, Keith P, Strutton, David R, Weinstein, Milton C

“…High rates of bacterial coinfection in autopsy data from the 2009 H1N1 influenza ("flu") pandemic suggest synergies between flu and pneumococcal disease (PD)…”
Get full text

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine by Isaacman, Daniel J., MD, Strutton, David R., PhD, Kalpas, Edward A., MD, Horowicz-Mehler, Nathalie, MS, Stern, Lee S., MS, Casciano, Roman, MS, Ciuryla, Vincent, PhD

“…Abstract Background: The heptavalent pneumococcal polysaccharide-protein conjugate vaccine (PCV7) confers protection against invasive pneumococcal disease…”
Get full text

Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions by Weycker, Derek, Farkouh, Raymond A, Strutton, David R, Edelsberg, John, Shea, Kimberly M, Pelton, Stephen I

“…The presence of certain underlying medical conditions is known to increase the risk of pneumococcal disease in persons of all ages and across a wide spectrum…”
Get full text

Risk of Pneumococcal Disease in Children With Chronic Medical Conditions in the Era of Pneumococcal Conjugate Vaccine by Pelton, Stephen I., Weycker, Derek, Farkouh, Raymond A., Strutton, David R., Shea, Kimberly M., Edelsberg, John

“…Background. In the current era of universal immunization of young children with pneumococcal conjugate vaccine, it is unclear whether the high risk ratios for…”
Get full text

Rates of pneumococcal disease in adults with chronic medical conditions by Shea, Kimberly M, Edelsberg, John, Weycker, Derek, Farkouh, Raymond A, Strutton, David R, Pelton, Stephen I

“…Although it is widely accepted that adults with immunocompromising conditions are at greatly increased risk of pneumococcal infection, the extent of risk among…”
Get full text

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data by Strutton, David R, Farkouh, Raymond A, Rubin, Jaime L, McGarry, Lisa J, Loiacono, Paul M, Klugman, Keith P, Pelton, Steven I, Gilmore, Kristen E, Weinstein, Milton C

“…Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort…”
Get full text

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic by Rubin, Jaime L, McGarry, Lisa J, Klugman, Keith P, Strutton, David R, Gilmore, Kristen E, Weinstein, Milton C

“…Influenza pandemic outbreaks occurred in the US in 1918, 1957, and 1968. Historical evidence suggests that the majority of influenza-related deaths during the…”
Get full text

US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey by Strutton, David R, Kowalski, Jonathan W, PharmD, Glaser, Dee Anna, Stang, Paul E

“…The current epidemiologic data on hyperhidrosis are scarce and insufficient to provide precise prevalence or impact estimates. We sought to estimate the…”
Get full text

Rates of pneumonia among children and adults with chronic medical conditions in Germany by Pelton, Stephen I, Shea, Kimberly M, Farkouh, Raymond A, Strutton, David R, Braun, Sebastian, Jacob, Christian, Klok, Rogier, Gruen, Elana S, Weycker, Derek

“…The objective of this study is to evaluate rates of all-cause pneumonia among "at-risk" and "high-risk" children and adults in Germany-in comparison with…”
Get full text

Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia by Strutton, David R, Gutierrez, Benjamin, Blanchette, Christopher M

“…The influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia was studied. Patients hospitalized with a primary…”
Get full text

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands by Strutton, David R, Farkouh, Raymond A, Earnshaw, Stephanie R, Hwang, Sharon, Theidel, Ulrike, Kontodimas, Stathis, Klok, Rogier, Papanicolaou, Sotiria

“…Summary Background Seven-valent pneumococcal conjugate vaccine (PCV7) had profound public-health impacts and is considered cost-effective and potentially cost…”
Get full text

Cost-effectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States by Ray, G. Thomas, Pelton, Stephen I, Klugman, Keith P, Strutton, David R, Moore, Matthew R

“…Abstract Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the United States since 2000 and data have indicated direct and indirect…”
Get full text

Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion by Kohli, Michele A, Farkouh, Raymond A, Maschio, Michael J, McGarry, Lisa J, Strutton, David R, Weinstein, Milton C

“…In 2010 the US Advisory Committee on Immunization Practices recommended that the seven-valent pneumococcal conjugate vaccine (PCV7) be replaced by the…”
Get full text

Rethinking risk for pneumococcal disease in adults: the role of risk stacking by Pelton, Stephen I, Shea, Kimberly M, Weycker, Derek, Farkouh, Raymond A, Strutton, David R, Edelsberg, John

“…Using data from 3 private healthcare claims repositories, we evaluated the incidence of pneumococcal disease among adults with US Advisory Committee on…”
Get full text

The authors respond by Klok, Rogier M, Lindkvist, Rose-Marie, Ekelund, Mats, Farkouh, Raymond A, Strutton, David R

Get full text

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions by Farkouh, Raymond A, Klok, Rogier M, Postma, Maarten J, Roberts, Craig S, Strutton, David R

“…Currently, 13-valent pneumococcal conjugate vaccine (PCV); and ten-valent PCV vaccine are marketed. Neither vaccine obtained regulatory approval based on…”
Get more information

Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations by Snedecor, Sonya J, Strutton, David R, Ciuryla, Vincent, Schwartz, Elissa J, Botteman, Marc F

“…Abstract We developed an age-structured, transmission-dynamic, mathematical model to quantify the direct and indirect benefits of infant PCV7 vaccination. The…”
Get full text

Trends in Glaucoma Surgery before and after the Introduction of New Topical Glaucoma Pharmacotherapies by Strutton, David R, Walt, John G

“…OBJECTIVE:Recent advances in pharmacotherapy that have improved the ability to effect sustained reductions in intraocular pressure may delay or obviate the…”
Get full text